Cargando…
Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers
Our aim was to evaluate the immune response of healthcare workers included in the RIPOVAC study, after receiving a booster dose (third dose), in terms of intensity and persistence of induced antibodies. In the second phase of the RIPOVAC study, between December 2021 and January 2022, eight months af...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341794/ https://www.ncbi.nlm.nih.gov/pubmed/37445893 http://dx.doi.org/10.3390/ijms241310713 |
_version_ | 1785072346632028160 |
---|---|
author | Algarate, Sonia Serrano, Laura Bueno, Jessica Herrero-Cortina, Beatriz Alvarado, Elena González-Barriga, María T. Ducons, María Montero-Marco, Jesica Arnal, Sara Acha, Beatriz Riesgo, María Taboada, Ana Sanz-Burillo, Pilar Yuste, Cristina Benito, Rafael |
author_facet | Algarate, Sonia Serrano, Laura Bueno, Jessica Herrero-Cortina, Beatriz Alvarado, Elena González-Barriga, María T. Ducons, María Montero-Marco, Jesica Arnal, Sara Acha, Beatriz Riesgo, María Taboada, Ana Sanz-Burillo, Pilar Yuste, Cristina Benito, Rafael |
author_sort | Algarate, Sonia |
collection | PubMed |
description | Our aim was to evaluate the immune response of healthcare workers included in the RIPOVAC study, after receiving a booster dose (third dose), in terms of intensity and persistence of induced antibodies. In the second phase of the RIPOVAC study, between December 2021 and January 2022, eight months after the second dose, 389 voluntary, immunocompetent, non-pregnant healthcare workers received a booster dose of SARS-CoV-2 vaccine, and a serum sample was obtained. Two groups of patients were established: with and without previous SARS-CoV-2 infection. In order to quantify anti-S1 IgG (AU/mL) we used CMIA (Abbott). All of the health workers were anti-S IgG positive 8 months after receiving the booster dose of the vaccine, with a mean of 17,040 AU/mL. In 53 patients without previous infection, antibody levels increased by a mean of 10,762 AU/mL. This figure is seven times higher than the one produced after the second dose (1506 AU/mL). The booster dose produces a robust elevation of the antibody level, which persists at 8 months, with levels significantly higher than those reached after the second dose, which allow one to predict a persistence of more than one year. The study demonstrates the efficacy of the booster dose of anti-SARS-CoV-2 vaccines. |
format | Online Article Text |
id | pubmed-10341794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103417942023-07-14 Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers Algarate, Sonia Serrano, Laura Bueno, Jessica Herrero-Cortina, Beatriz Alvarado, Elena González-Barriga, María T. Ducons, María Montero-Marco, Jesica Arnal, Sara Acha, Beatriz Riesgo, María Taboada, Ana Sanz-Burillo, Pilar Yuste, Cristina Benito, Rafael Int J Mol Sci Brief Report Our aim was to evaluate the immune response of healthcare workers included in the RIPOVAC study, after receiving a booster dose (third dose), in terms of intensity and persistence of induced antibodies. In the second phase of the RIPOVAC study, between December 2021 and January 2022, eight months after the second dose, 389 voluntary, immunocompetent, non-pregnant healthcare workers received a booster dose of SARS-CoV-2 vaccine, and a serum sample was obtained. Two groups of patients were established: with and without previous SARS-CoV-2 infection. In order to quantify anti-S1 IgG (AU/mL) we used CMIA (Abbott). All of the health workers were anti-S IgG positive 8 months after receiving the booster dose of the vaccine, with a mean of 17,040 AU/mL. In 53 patients without previous infection, antibody levels increased by a mean of 10,762 AU/mL. This figure is seven times higher than the one produced after the second dose (1506 AU/mL). The booster dose produces a robust elevation of the antibody level, which persists at 8 months, with levels significantly higher than those reached after the second dose, which allow one to predict a persistence of more than one year. The study demonstrates the efficacy of the booster dose of anti-SARS-CoV-2 vaccines. MDPI 2023-06-27 /pmc/articles/PMC10341794/ /pubmed/37445893 http://dx.doi.org/10.3390/ijms241310713 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Algarate, Sonia Serrano, Laura Bueno, Jessica Herrero-Cortina, Beatriz Alvarado, Elena González-Barriga, María T. Ducons, María Montero-Marco, Jesica Arnal, Sara Acha, Beatriz Riesgo, María Taboada, Ana Sanz-Burillo, Pilar Yuste, Cristina Benito, Rafael Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers |
title | Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers |
title_full | Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers |
title_fullStr | Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers |
title_full_unstemmed | Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers |
title_short | Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers |
title_sort | persistence of anti-s1 igg against sars-cov-2 eight months after the booster dose of vaccine in naive and previously infected healthcare workers |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341794/ https://www.ncbi.nlm.nih.gov/pubmed/37445893 http://dx.doi.org/10.3390/ijms241310713 |
work_keys_str_mv | AT algaratesonia persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers AT serranolaura persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers AT buenojessica persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers AT herrerocortinabeatriz persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers AT alvaradoelena persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers AT gonzalezbarrigamariat persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers AT duconsmaria persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers AT monteromarcojesica persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers AT arnalsara persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers AT achabeatriz persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers AT riesgomaria persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers AT taboadaana persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers AT sanzburillopilar persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers AT yustecristina persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers AT benitorafael persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers AT persistenceofantis1iggagainstsarscov2eightmonthsaftertheboosterdoseofvaccineinnaiveandpreviouslyinfectedhealthcareworkers |